M. Lanasa
AstraZeneca
13 Papers
72 Citations
M. Lanasa is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Olaparib. The author has an hindex of 9, co-authored 13 publications.
Chat about Author
Papers
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Susan M. Domchek,Sophie Postel-Vinay,Sophie Postel-Vinay,Sophie Postel-Vinay,Seock-Ah Im,Yeon Hee Park,Jean Pierre Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,Sara Bastian,Matthew G Krebs,Matthew G Krebs,Ding Wang,Saiama N. Waqar,M. Lanasa,Joon Rhee,Haiyan Gao,Vidalba Rocher-Ros,Emma V. Jones,Sakshi Gulati,Anna M. L. Coenen-Stass,Iwanka Kozarewa,Zhongwu Lai,Helen K. Angell,L Opincar,P. Herbolsheimer,Bella Kaufman,Bella Kaufman +28 more
TL;DR: Combination of olaparib and durvalumab showed promising antitumour activity and safety similar to that previously observed in olapARib and DurvalumAB monotherapy studies.
357
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi,Do Youn Oh,Antoine Hollebecque,Emiliano Calvo,Anna M. Varghese,Erkut Borazanci,Teresa Macarulla,Valeria Merz,Camilla Zecchetto,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Leena Gandhi,Shawn T. Estrem,Karim A. Benhadji,M. Lanasa,Emin Avsar,Susan C. Guba,Rocio Garcia-Carbonero +18 more
TL;DR: In this paper, the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor Galunisertib co-administered with the anti-programmed deathligand 1 (PD-L1) antibody durvalumab in recurrent/refractory metastatic pancreatic cancer previously treated with ≤2 systemic regimens were assessed.
130
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Yvette Drew,Bella Kaufman,Susana Banerjee,A. Lortholary,Sook-Hee Hong,Young-Ae Park,Stefan Zimmermann,Patricia Roxburgh,M. Ferguson,Ricardo H. Alvarez,Susan M. Domchek,C. Gresty,Helen K. Angell,V Rocher Ros,K. Meyer,M. Lanasa,P. Herbolsheimer,M.J.A. de Jonge +17 more
TL;DR: The combination of olaparib and durvalumab was well tolerated and showed promising median PFS and DoR, and this cohort has been expanded to further explore the durability of this chemotherapy-sparing combination.
84
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
TL;DR: The CALLA trial is designed to determine the efficacy and safety of the programmed cell death-ligand 1 blocking antibody, durvalumab, with and following concurrent chemoradiotherapy versus concurrent cheMoradiotherapy alone in women with locally advanced cervical cancer.
77
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Susan M. Domchek,Sophie Postel-Vinay,S.-A. Im,Young-Ae Park,J.-P. Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,S Bastian,Matthew G Krebs,Ding Wang,S. Waqar,M. Lanasa,Helen K. Angell,Zhongwu Lai,C. Gresty,L Opincar,P. Herbolsheimer,Bella Kaufman +18 more
TL;DR: The data suggest that pts with fewer prior lines of chemotherapy (0/1) had higher ORR, longer mDoR, mPFS and mOS than those with 2 prior lines.
51